February 11, 2021
Gilead Sciences and Bristol-Myers Squibb urged a California federal judge Thursday to nix direct buyers' claims alleging the pharmaceutical companies engaged in anti-competitive conduct to block generic competition and keep HIV medication prices artificially high, arguing the suits should be sent to arbitration or thrown out as time-barred.